| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 16.4 | 16.9 | 16.7 |
| Other income | 0.0 | 0.4 | 0.0 |
| Total income | 16.4 | 17.2 | 16.7 |
| Profit before exceptional items & tax | 0.4 | 0.7 | 0.3 |
| Profit before tax | 0.4 | 0.7 | 0.3 |
| Net profit | 0.2 | 0.0 | 0.2 |
| Operating margin | 2.4% | 4.1% | 1.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +0.00% |
|---|---|
| Revenue, year on year | -1.80% |
| Operating profit, year on year | +33.30% |
| Operating profit, quarter on quarter | +33.30% |
BSE results filing, NSE: SANDUPHQ. Figures extracted from the filing.
Sandu Pharmaceuticals Ltd: key numbers
- Share price
- ₹37.00
- Market cap
- ₹35.75 Cr
- Revenue (annual)
- ₹69.93 Cr
- Net profit (annual)
- ₹1.77 Cr
- P/E (TTM)
- 14.7×Sector 50.4×
- Promoter holding
- 37.79%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sandu Pharmaceuticals Ltd
All →Sandu Pharmaceuticals Management Change
Sandu Pharmaceuticals appointed Dr. Neeti Madan Kapre as director and Dave & Dave as statutory auditor, while announcing other board and auditor tenure changes.
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals has appointed M/s. Dave & Dave as Statutory Auditors for a five-year term, following the tenure expiry of the previous auditors.
Sandu Pharmaceuticals Annual General Meeting
Sandu Pharmaceuticals Limited held its 41st Annual General Meeting on September 11, 2026, via video conferencing to transact ordinary and special business items.
Sandu Pharmaceuticals Q4 FY26 Results: Net Profit ₹0 Cr
Sandu Pharmaceuticals Ltd reported revenue from operations of ₹16.9 Cr (+19.9% YoY) and net profit of ₹0 Cr for Q4 FY26.
- Key figure
- Net profit ₹0 Cr